Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases

Christophe M. Raynaud, Olaf Mercier, Frederic Commo, Philippe Dartevelle, Carlos Gomez-Roca, Vincent de Montpreville, Laure Sabatier, Jean Charles Soria

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: The development of molecular targeted therapies as anti-cancer strategies raises important questions regarding the biological and molecular behavior of the metastatic sites as compared to their corresponding primary tumors. We analysed telomere related markers (telomere length and telomeric proteins) and DNA damage repair (DDR) markers in a cohort of patients with surgically resected primary lung NSCLC and adrenal metastasis. These markers were selected for two reasons: (i) small molecule inhibitors of 'druggable' DDR components as well as telomere-interacting agents are already being developed for clinical use; and (ii) limited data is available comparing the expression of these biomarkers between primary tumors and their metastases. Material and methods: We studied a single series of 21 patients who had undergone surgery of both their primary lung tumor and its related adrenal gland metastasis in a single Institution. DDR and telomeric proteins were analysed by immunohistochemistry and telomere length was assessed by fluorescent in situ hybridization in 17 paired samples. Results: DDR activation was observed in primary tumors and their corresponding metastasis. However, higher levels of p-Chk2 were observed in metastasis than in primary tumors (p = 0.0113). This was not observed for p-ATM and γ-H2AX. Telomere length was independent from primary or metastatic status (p = 0.29). There was no correlation between primary and metastatic sites, although ∼65% of metastases had shorter telomeres than their corresponding primary tumors. In the same way, telomeric protein expression was independent from primary/metastatic localization. Cluster analysis of each specimen according to its protein's expression levels and telomere length showed that matched primary tumors/adrenal metastasis were mostly separated into different clusters. Overall, our findings suggest that the levels of biomarkers analysed differ substantially between primary lung tumors and corresponding metastases. Conclusion: There are clear molecular discrepancies at the telomeric and DDR level between primary tumors and their corresponding metastases. Our results may have important implications for the development of molecular targeted therapies aiming at DNA damage repair and telomeric components. Our findings suggest that primary tumors and their relevant metastases may respond differently to such approaches.

Original languageEnglish
Pages (from-to)144-149
Number of pages6
JournalLung Cancer
Volume65
Issue number2
DOIs
Publication statusPublished - 1 Aug 2009
Externally publishedYes

Fingerprint

Telomere
DNA Repair
DNA Damage
Neoplasm Metastasis
Lung
Neoplasms
Proteins
Molecular Targeted Therapy
Biomarkers
Adrenal Glands
Fluorescence In Situ Hybridization
Cluster Analysis
Immunohistochemistry

Keywords

  • DNA damage repair
  • Lung cancer
  • Metastasis
  • Telomere length
  • Telomeric proteins

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. / Raynaud, Christophe M.; Mercier, Olaf; Commo, Frederic; Dartevelle, Philippe; Gomez-Roca, Carlos; de Montpreville, Vincent; Sabatier, Laure; Soria, Jean Charles.

In: Lung Cancer, Vol. 65, No. 2, 01.08.2009, p. 144-149.

Research output: Contribution to journalArticle

Raynaud, Christophe M. ; Mercier, Olaf ; Commo, Frederic ; Dartevelle, Philippe ; Gomez-Roca, Carlos ; de Montpreville, Vincent ; Sabatier, Laure ; Soria, Jean Charles. / Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases. In: Lung Cancer. 2009 ; Vol. 65, No. 2. pp. 144-149.
@article{ebaef5ff17964b7db3ce07823953ac22,
title = "Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases",
abstract = "Introduction: The development of molecular targeted therapies as anti-cancer strategies raises important questions regarding the biological and molecular behavior of the metastatic sites as compared to their corresponding primary tumors. We analysed telomere related markers (telomere length and telomeric proteins) and DNA damage repair (DDR) markers in a cohort of patients with surgically resected primary lung NSCLC and adrenal metastasis. These markers were selected for two reasons: (i) small molecule inhibitors of 'druggable' DDR components as well as telomere-interacting agents are already being developed for clinical use; and (ii) limited data is available comparing the expression of these biomarkers between primary tumors and their metastases. Material and methods: We studied a single series of 21 patients who had undergone surgery of both their primary lung tumor and its related adrenal gland metastasis in a single Institution. DDR and telomeric proteins were analysed by immunohistochemistry and telomere length was assessed by fluorescent in situ hybridization in 17 paired samples. Results: DDR activation was observed in primary tumors and their corresponding metastasis. However, higher levels of p-Chk2 were observed in metastasis than in primary tumors (p = 0.0113). This was not observed for p-ATM and γ-H2AX. Telomere length was independent from primary or metastatic status (p = 0.29). There was no correlation between primary and metastatic sites, although ∼65{\%} of metastases had shorter telomeres than their corresponding primary tumors. In the same way, telomeric protein expression was independent from primary/metastatic localization. Cluster analysis of each specimen according to its protein's expression levels and telomere length showed that matched primary tumors/adrenal metastasis were mostly separated into different clusters. Overall, our findings suggest that the levels of biomarkers analysed differ substantially between primary lung tumors and corresponding metastases. Conclusion: There are clear molecular discrepancies at the telomeric and DDR level between primary tumors and their corresponding metastases. Our results may have important implications for the development of molecular targeted therapies aiming at DNA damage repair and telomeric components. Our findings suggest that primary tumors and their relevant metastases may respond differently to such approaches.",
keywords = "DNA damage repair, Lung cancer, Metastasis, Telomere length, Telomeric proteins",
author = "Raynaud, {Christophe M.} and Olaf Mercier and Frederic Commo and Philippe Dartevelle and Carlos Gomez-Roca and {de Montpreville}, Vincent and Laure Sabatier and Soria, {Jean Charles}",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.lungcan.2008.10.030",
language = "English",
volume = "65",
pages = "144--149",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases

AU - Raynaud, Christophe M.

AU - Mercier, Olaf

AU - Commo, Frederic

AU - Dartevelle, Philippe

AU - Gomez-Roca, Carlos

AU - de Montpreville, Vincent

AU - Sabatier, Laure

AU - Soria, Jean Charles

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Introduction: The development of molecular targeted therapies as anti-cancer strategies raises important questions regarding the biological and molecular behavior of the metastatic sites as compared to their corresponding primary tumors. We analysed telomere related markers (telomere length and telomeric proteins) and DNA damage repair (DDR) markers in a cohort of patients with surgically resected primary lung NSCLC and adrenal metastasis. These markers were selected for two reasons: (i) small molecule inhibitors of 'druggable' DDR components as well as telomere-interacting agents are already being developed for clinical use; and (ii) limited data is available comparing the expression of these biomarkers between primary tumors and their metastases. Material and methods: We studied a single series of 21 patients who had undergone surgery of both their primary lung tumor and its related adrenal gland metastasis in a single Institution. DDR and telomeric proteins were analysed by immunohistochemistry and telomere length was assessed by fluorescent in situ hybridization in 17 paired samples. Results: DDR activation was observed in primary tumors and their corresponding metastasis. However, higher levels of p-Chk2 were observed in metastasis than in primary tumors (p = 0.0113). This was not observed for p-ATM and γ-H2AX. Telomere length was independent from primary or metastatic status (p = 0.29). There was no correlation between primary and metastatic sites, although ∼65% of metastases had shorter telomeres than their corresponding primary tumors. In the same way, telomeric protein expression was independent from primary/metastatic localization. Cluster analysis of each specimen according to its protein's expression levels and telomere length showed that matched primary tumors/adrenal metastasis were mostly separated into different clusters. Overall, our findings suggest that the levels of biomarkers analysed differ substantially between primary lung tumors and corresponding metastases. Conclusion: There are clear molecular discrepancies at the telomeric and DDR level between primary tumors and their corresponding metastases. Our results may have important implications for the development of molecular targeted therapies aiming at DNA damage repair and telomeric components. Our findings suggest that primary tumors and their relevant metastases may respond differently to such approaches.

AB - Introduction: The development of molecular targeted therapies as anti-cancer strategies raises important questions regarding the biological and molecular behavior of the metastatic sites as compared to their corresponding primary tumors. We analysed telomere related markers (telomere length and telomeric proteins) and DNA damage repair (DDR) markers in a cohort of patients with surgically resected primary lung NSCLC and adrenal metastasis. These markers were selected for two reasons: (i) small molecule inhibitors of 'druggable' DDR components as well as telomere-interacting agents are already being developed for clinical use; and (ii) limited data is available comparing the expression of these biomarkers between primary tumors and their metastases. Material and methods: We studied a single series of 21 patients who had undergone surgery of both their primary lung tumor and its related adrenal gland metastasis in a single Institution. DDR and telomeric proteins were analysed by immunohistochemistry and telomere length was assessed by fluorescent in situ hybridization in 17 paired samples. Results: DDR activation was observed in primary tumors and their corresponding metastasis. However, higher levels of p-Chk2 were observed in metastasis than in primary tumors (p = 0.0113). This was not observed for p-ATM and γ-H2AX. Telomere length was independent from primary or metastatic status (p = 0.29). There was no correlation between primary and metastatic sites, although ∼65% of metastases had shorter telomeres than their corresponding primary tumors. In the same way, telomeric protein expression was independent from primary/metastatic localization. Cluster analysis of each specimen according to its protein's expression levels and telomere length showed that matched primary tumors/adrenal metastasis were mostly separated into different clusters. Overall, our findings suggest that the levels of biomarkers analysed differ substantially between primary lung tumors and corresponding metastases. Conclusion: There are clear molecular discrepancies at the telomeric and DDR level between primary tumors and their corresponding metastases. Our results may have important implications for the development of molecular targeted therapies aiming at DNA damage repair and telomeric components. Our findings suggest that primary tumors and their relevant metastases may respond differently to such approaches.

KW - DNA damage repair

KW - Lung cancer

KW - Metastasis

KW - Telomere length

KW - Telomeric proteins

UR - http://www.scopus.com/inward/record.url?scp=67449163726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449163726&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2008.10.030

DO - 10.1016/j.lungcan.2008.10.030

M3 - Article

VL - 65

SP - 144

EP - 149

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -